奥曲肽联合加贝酯治疗重症急性胰腺炎临床疗效的初步探讨

Preliminary study of clinical curative effect of octreotide combined with gabexate in the treatment of severe acute pancreatitis

摘要:

目的：初步探讨奥曲肽联合加贝酯治疗重症急性胰腺炎（severe acute pancreatitis，SAP）的临床疗效。方法：将2008年10月到2010年10月我院收治的ＳＡＰ46例患者随机分为A、B ２组，每组23例；A组：奥曲肽联合加贝酯治疗，B组：奥曲肽治疗。观察２组患者腹部体征消失、胃肠道功能恢复正常时间，2组总有效率和并发症发生率。结果：A组腹部体征消失、胃肠道功能恢复正常时间均低于B组（P<0.05），A组总有效率高于B组，但差异无统计学意义（P >0.05），并发症发生率、手术率A组（13.04%）低于B组（30.43%）。结论：奥曲肽联合加贝酯治疗ＳＡＰ临床疗效较好，可提高总有效率和降低并发症发生率。

Abstract:

Objective：To preliminary discuss clinical curative effect of octreotide combined with gabexate in the treatment of severe a－cute pancreatitis（SAP）. Methods：Totally 46 patients with SAP from October 2008 to October 2010 in our hospital were randomly di－vided into groups A（n=23） and B（n=23）. Octreotide combined with gabexate were used in group A while only octreotide was used in group B. Patients’ normal time of disappearance of abdominal signs，recovery of gastrointestinal function and recovery of hematuria amylase in two groups were observed. Total effective rate and complication incidence in two groups were observed. Results：Time of abdominal signs’ disappearance，gastrointestinal function’s recovery and hematuria amylase’s recovery were shorter in group A than in group B（P<0.05）. Total effective rate in group A is higher than that in group B，but without significant differences（P<0.05）. Inci－dence of complication and operation rate in group A（13.04%） was lower than that in group B（30.43%）. Conclusions：Octreotide combined with gabexate is the better choice in the treatment of SAP，which can improve the total effective rate and reduce complica－tion incidence.